Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

Cellular and Molecular Life Sciences

Volumn 67, Issue 21, 2010, Pages 3663-3681

  Kaina, Bernd ^a   Margison, Geoffrey P ^b   Christmann, Markus ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alkyltransferase; Drug resistance; Glioblastoma; Inhibitor targeting; Melanoma; MGMT; O 6 benzylguanine; Repair inhibitors

Indexed keywords

6 O BENZYL 2' DEOXYGUANOSINE; 6 O BENZYLGUANINE; CARMUSTINE; CYCLOPHOSPHAMIDE; DEOXYGUANOSINE DERIVATIVE; IRINOTECAN; LOMEGUATRIB; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NIMUSTINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; ENZYME INHIBITOR;

ACUTE LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL KILLING; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; DEALKYLATION; DIARRHEA; DISTRIBUTION VOLUME; DNA ADDUCT; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DOUBLE STRANDED DNA BREAK; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; GENE TRANSFER; GLIOBLASTOMA; GLIOMA; HODGKIN DISEASE; HUMAN; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; LUNG CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MELANOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROBLASTOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS TUMOR; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMACH ADENOCARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR REGRESSION; ANIMAL; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; NEOPLASMS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 78149469118     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-010-0491-7     Document Type: Review

References (145)

1. P Kleihues PN Magee 1973 Alkylation of rat brain nucleic acids by N-methyl-N-nitrosourea and methyl methanesulphonate J Neurochem 20 595 606 4698302
2. HE Skipper FM Schabel Jr MW Trader JR Thomson 1961 Experimental evaluation of potential anticancer agents. VI. Anatomical distribution of leukemic cells and failure of chemotherapy Cancer Res 21 1154 1164 13913645
3. DB Ludlum 1990 DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal Mutat Res 233 117 126 2233793
4. M Goldstein WP Roos B Kaina 2008 Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling Toxicol Appl Pharmacol 229 20 32 18289623
5. I Preuss R Thust B Kaina 1996 Protective effect of O6-methylguanine-DNA methyltransferase (MGMT) on the cytotoxic and recombinogenic activity of different antineoplastic drugs Int J Cancer 65 506 512 8621235
6. HS Friedman AE Pegg SP Johnson NA Loktionova ME Dolan P Modrich RC Moschel R Struck TP Brent S Ludeman N Bullock C Kilborn S Keir Q Dong DD Bigner OM Colvin 1999 Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferase Cancer Chemother Pharmacol 43 80 85 9923545
7. ME Dolan RB Mitchell C Mummert RC Moschel AE Pegg 1991 Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents Cancer Res 51 3367 3372 1647266
8. B Kaina M Christmann S Naumann WP Roos 2007 MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair (Amst) 6 1079 1099
9. SC Naumann WP Roos E Jost C Belohlavek V Lennerz CW Schmidt M Christmann B Kaina 2009 Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53 Br J Cancer 100 322 333 19127257
10. WP Roos LF Batista SC Naumann W Wick M Weller CF Menck B Kaina 2007 Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine Oncogene 26 186 197 16819506
11. S Quiros WP Roos B Kaina 2010 Processing of O6-methylguanine into DNA double-strand breaks requires two rounds of replication whereas apoptosis is also induced in subsequent cell cycles Cell Cycle 9 168 178 20016283
12. G Fritz K Tano S Mitra B Kaina 1991 Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments Mol Cell Biol 11 4660 4668 1875945
13. KS Srivenugopal SR Mullapudi J Shou TK Hazra F Ali-Osman 2000 Protein phosphorylation is a regulatory mechanism for O6-alkylguanine-DNA alkyltransferase in human brain tumor cells Cancer Res 60 282 287 10667577
14. SR Mullapudi F Ali-Osman J Shou KS Srivenugopal 2000 DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells Biochem J 351 Pt 2 393 402 11023825
15. TK Hazra R Roy T Biswas DT Grabowski AE Pegg S Mitra 1997 Specific recognition of O6-methylguanine in DNA by active site mutants of human O6-methylguanine-DNA methyltransferase Biochemistry 36 5769 5776 9153417
16. AE Pegg ME Dolan RC Moschel 1995 Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase Prog Nucleic Acid Res Mol Biol 51 167 223 7659775
17. B Kaina G Fritz S Mitra T Coquerelle 1991 Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents Carcinogenesis 12 1857 1867 1657427
18. KS Srivenugopal XH Yuan HS Friedman F Ali-Osman 1996 Ubiquitination- dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea Biochemistry 35 1328 1334 8573590
19. P Kleihues GP Margison 1976 Exhaustion and recovery of repair excision of O6-methylguanine from rat liver DNA Nature 259 153 155 1246354
20. J Lips B Kaina 2001 Repair of O(6)-methylguanine is not affected by thymine base pairing and the presence of MMR proteins Mutat Res 487 59 66 11595409
21. PE Gonzaga PM Potter TQ Niu D Yu DB Ludlum JA Rafferty GP Margison TP Brent 1992 Identification of the cross-link between human O6-methylguanine-DNA methyltransferase and chloroethylnitrosourea-treated DNA Cancer Res 52 6052 6058 1394230
22. JG Hengstler B Tanner L Moller R Meinert B Kaina 1999 Activity of O(6)-methylguanine-DNA methyltransferase in relation to p53 status and therapeutic response in ovarian cancer Int J Cancer 84 388 395 10404091
23. AK Teo HK Oh RB Ali BF Li 2001 The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage Mol Cell Biol 21 7105 7114 11564893
24. SL Gerson W Phillips M Kastan LL Dumenco C Donovan 1996 Human CD34 + hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU Blood 88 1649 1655 8781420
25. UR Sorg V Kleff S Fanaei A Schumann M Moellmann B Opalka J Thomale T Moritz 2007 O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues DNA Repair (Amst) 6 1197 1209
26. M Citron A White R Decker P Wasserman B Li T Randall D Guerra M Belanich D Yarosh 1995 O6-methylguanine-DNA methyltransferase in human brain tumors detected by activity assay and monoclonal antibodies Oncol Res 7 49 55 7549044
27. I Preuss S Haas U Eichhorn I Eberhagen M Kaufmann T Beck RH Eibl P Dall T Bauknecht J Hengstler BM Wittig W Dippold B Kaina 1996 Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue Cancer Detect Prev 20 130 136 8706038
28. GP Margison AC Povey B Kaina MF Santibanez Koref 2003 Variability and regulation of O(6)-alkylguanine-DNA alkyltransferase Carcinogenesis 24 625 635 12727789
29. D Wiewrodt G Nagel N Dreimuller T Hundsberger A Perneczky B Kaina 2008 MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome Int J Cancer 122 1391 1399 18000822
30. K Janssen U Eichhorn-Grombacher K Schlink S Nitzsche F Oesch B Kaina 2001 Long-time expression of DNA repair enzymes MGMT and APE in human peripheral blood mononuclear cells Arch Toxicol 75 306 312 11548124
31. S Egyhazi GP Margison J Hansson U Ringborg 1997 Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases Eur J Cancer 33 129 134 9071912
32. P Rietschel JD Wolchok S Krown S Gerst AA Jungbluth K Busam K Smith I Orlow K Panageas PB Chapman 2008 Phase II study of extended-dose temozolomide in patients with melanoma J Clin Oncol 26 2299 2304 18467721
33. M Esteller SR Hamilton PC Burger SB Baylin JG Herman 1999 Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 793 797 10029064
34. ME Hegi AC Diserens S Godard PY Dietrich L Regli S Ostermann P Otten G Van Melle N de Tribolet R Stupp 2004 Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide Clin Cancer Res 10 1871 1874 15041700
35. ME Hegi AC Diserens T Gorlia MF Hamou N de Tribolet M Weller JM Kros JA Hainfellner W Mason L Mariani JE Bromberg P Hau RO Mirimanoff JG Cairncross RC Janzer R Stupp 2005 MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 997 1003 15758010
36. M Esteller J Garcia-Foncillas E Andion SN Goodman OF Hidalgo V Vanaclocha SB Baylin JG Herman 2000 Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 1350 1354 11070098
37. Christmann M, Nagel G, Horn S, Krahn U, Wiewrodt D, Sommer C, Kaina B (2010) MGMT activity, promoter methylation and immunohistochemistry of pre-treatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer (Epub ahead of print)
38. M Weller R Stupp G Reifenberger AA Brandes MJ van den Bent W Wick ME Hegi 2009 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 6 39 51 19997073
39. S Spiegl-Kreinecker C Pirker M Filipits D Lotsch J Buchroithner J Pichler R Silye S Weis M Micksche J Fischer W Berger 2010 O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients Neuro Oncol 12 28 36 20150365
40. CK Augustine JS Yoo A Potti Y Yoshimoto PA Zipfel HS Friedman JR Nevins F Ali-Osman DS Tyler 2009 Genomic and molecular profiling predicts response to temozolomide in melanoma Clin Cancer Res 15 502 510 19147755
41. R Stupp WP Mason MJ van den Bent M Weller B Fisher MJ Taphoorn K Belanger AA Brandes C Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer RO Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 15758009
42. Sabharwal A, Waters R, Danson S, Clamp A, Lorigan P, Thatcher N, Margison GP, Middleton MR (2009) Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mononuclear cells. Melanoma Res (Epub ahead of print)
43. C Zlotogorski LC Erickson 1983 Pretreatment of normal human fibroblasts and human colon carcinoma cells with MNNG allows chloroethylnitrosourea to produce DNA interstrand crosslinks not observed in cells treated with chloroethylnitrosourea alone Carcinogenesis 4 759 763 6861280
44. C Zlotogorski LC Erickson 1984 Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts Carcinogenesis 5 83 87 6690090
45. SL Gerson NA Berger C Arce SJ Petzold JK Willson 1992 Modulation of nitrosourea resistance in human colon cancer by O6-methylguanine Biochem Pharmacol 43 1101 1107 1554383
46. ME Dolan K Morimoto AE Pegg 1985 Reduction of O6-alkylguanine-DNA alkyltransferase activity in HeLa cells treated with O6-alkylguanines Cancer Res 45 6413 6417 4063990 (Pubitemid 16224819)
47. DB Yarosh S Hurst-Calderone MA Babich RS Day 3rd 1986 Inactivation of O6-methylguanine-DNA methyltransferase and sensitization of human tumor cells to killing by chloroethylnitrosourea by O6-methylguanine as a free base Cancer Res 46 1663 1668 3948156
48. ME Dolan GL Larkin HF English AE Pegg 1989 Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine Cancer Chemother Pharmacol 25 103 108 2557168
49. ME Dolan RC Moschel AE Pegg 1990 Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents Proc Natl Acad Sci USA 87 5368 5372 2164681
50. RC Moschel MG McDougall ME Dolan L Stine AE Pegg 1992 Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase J Med Chem 35 4486 4491 1447749
51. MH Moore JM Gulbis EJ Dodson B Demple PC Moody 1994 Crystal structure of a suicidal DNA repair protein: the Ada O6-methylguanine-DNA methyltransferase from E. coli EMBO J 13 1495 1501 8156986
52. T Shibata N Glynn TB McMurry RS McElhinney GP Margison DM Williams 2006 Novel synthesis of O6-alkylguanine containing oligodeoxyribonucleotides as substrates for the human DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT) Nucleic Acids Res 34 1884 1891 16609128
53. B Kaina U Muhlhausen A Piee-Staffa M Christmann R Garcia Boy F Rosch R Schirrmacher 2004 Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death J Pharmacol Exp Ther 311 585 593 15254145
54. SK Roy KR Korzekwa FJ Gonzalez RC Moschel ME Dolan 1995 Human liver oxidative metabolism of O6-benzylguanine Biochem Pharmacol 50 1385 1389 7503788
55. L Long RC Moschel ME Dolan 2001 Debenzylation of O(6)-benzyl-8-oxoguanine in human liver: implications for O(6)-benzylguanine metabolism Biochem Pharmacol 61 721 726 11266657
56. SK Roy E Gupta ME Dolan 1995 Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes Drug Metab Dispos 23 1394 1399 8689950
57. SL Berg SL Gerson K Godwin DE Cole L Liu FM Balis 1995 Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate Cancer Res 55 4606 4610 7553637
58. SL Berg DJ Murry CL McCully K Godwin FM Balis 1998 Pharmacokinetics of O6-benzylguanine and its active metabolite 8-oxo-O6-benzylguanine in plasma and cerebrospinal fluid after intrathecal administration of O6-benzylguanine in the nonhuman primate Clin Cancer Res 4 2891 2894 9829757
59. ME Dolan SK Roy AA Fasanmade PR Paras RL Schilsky MJ Ratain 1998 O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings J Clin Oncol 16 1803 1810 9586894
60. K Neville S Blaney M Bernstein P Thompson D Adams A Aleksic S Berg 2004 Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study Clin Cancer Res 10 5072 5075 15297409
61. L Long SL Berg SK Roy CL McCully HW Song-Yoo RC Moschel FM Balis ME Dolan 2000 Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and analogues in nonhuman primates Clin Cancer Res 6 3662 3669 10999759
62. RB Ewesuedo LR Wilson HS Friedman RC Moschel ME Dolan 2001 Inactivation of O6-alkylguanine-DNA alkyltransferase by 8-substituted O6-benzylguanine analogs in mice Cancer Chemother Pharmacol 47 63 69 11221964
63. M Ranson MR Middleton J Bridgewater SM Lee M Dawson D Jowle G Halbert S Waller H McGrath L Gumbrell RS McElhinney D Donnelly TB McMurry GP Margison 2006 Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors Clin Cancer Res 12 1577 1584 16533784
64. HS Friedman ME Dolan RC Moschel AE Pegg GM Felker J Rich DD Bigner SC Schold Jr 1992 Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme J Natl Cancer Inst 84 1926 1931 1334154
65. SR Wedge JK Porteous ES Newlands 1997 Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model Cancer Chemother Pharmacol 40 266 272 9219512
66. Y Wan D Wu H Gao H Lu 2000 Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo J Environ Pathol Toxicol Oncol 19 69 75 10905510
67. UK Marathi ME Dolan LC Erickson 1994 Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo Biochem Pharmacol 48 2127 2134 7802703
68. EL Kreklau C Kurpad DA Williams LC Erickson 1999 Prolonged inhibition of O(6)-methylguanine DNA methyltransferase in human tumor cells by O(6)-benzylguanine in vitro and in vivo J Pharmacol Exp Ther 291 1269 1275 10565851
69. GM Felker HS Friedman ME Dolan RC Moschel C Schold 1993 Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea Cancer Chemother Pharmacol 32 471 476 8258196
70. DM Kokkinakis MM Ahmed D Chendil RC Moschel AE Pegg 2003 Sensitization of pancreatic tumor xenografts to carmustine and temozolomide by inactivation of their O6-methylguanine-DNA methyltransferase with O6-benzylguanine or O6-benzyl-2′-deoxyguanosine Clin Cancer Res 9 3801 3807 14506174
71. HS Friedman S Keir AE Pegg PJ Houghton OM Colvin RC Moschel DD Bigner ME Dolan 2002 O6-benzylguanine-mediated enhancement of chemotherapy Mol Cancer Ther 1 943 948 12481416
72. LM Wagner RE McLendon KJ Yoon BD Weiss CA Billups MK Danks 2007 Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma Clin Cancer Res 13 5418 5425 17875772
73. LD Rhines P Sampath ME Dolan BM Tyler H Brem J Weingart 2000 O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma Cancer Res 60 6307 6310 11103789
74. SC Schold Jr DM Kokkinakis JL Rudy RC Moschel AE Pegg 1996 Treatment of human brain tumor xenografts with O6-benzyl-2′-deoxyguanosine and BCNU Cancer Res 56 2076 2081 8616853
75. SR Wedge ES Newlands 1996 O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU Br J Cancer 73 1049 1052 8624262
76. ST Keir ME Dolan AE Pegg A Lawless RC Moschel DD Bigner HS Friedman 2000 O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer-central nervous system tumor xenografts-implications for clinical trials Cancer Chemother Pharmacol 45 437 440 10854129
77. SN Kurpad ME Dolan RE McLendon GE Archer RC Moschel AE Pegg DD Bigner HS Friedman 1997 Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea Cancer Chemother Pharmacol 39 307 316 9025771
78. T Ueno SH Ko E Grubbs Y Yoshimoto C Augustine Z Abdel-Wahab TY Cheng OI Abdel-Wahab SK Pruitt HS Friedman DS Tyler 2006 Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine Mol Cancer Ther 5 732 738 16546988
79. DM Kokkinakis RC Moschel AE Pegg SC Schold 2000 Potentiation of BCNU antitumor efficacy by 9-substituted O6-benzylguanines. Effect of metabolism Cancer Chemother Pharmacol 45 69 77 10647505
80. MR Middleton J Kelly N Thatcher DJ Donnelly RS McElhinney TB McMurry JE McCormick GP Margison 2000 O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts Int J Cancer 85 248 252 10629085 (Pubitemid 30023075)
81. MR Middleton J Kelly S Goodger N Thatcher GP Margison 2000 Four-hourly scheduling of temozolomide improves tumour growth delay but not therapeutic index in A375M melanoma xenografts Cancer Chemother Pharmacol 45 15 20 10647496 (Pubitemid 30099710)
82. MR Middleton N Thatcher TB McMurry RS McElhinney DJ Donnelly GP Margison 2002 Effect of O6-(4-bromothenyl)guanine on different temozolomide schedules in a human melanoma xenograft model Int J Cancer 100 615 617 12124813
83. M Clemons J Kelly AJ Watson A Howell RS McElhinney TB McMurry GP Margison 2005 O6-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts Br J Cancer 93 1152 1156 16278661
84. M Turriziani P Caporaso L Bonmassar F Buccisano S Amadori A Venditti M Cantonetti S D'Atri E Bonmassar 2006 O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro Pharmacol Res 53 317 323 16412662
85. HS Friedman DM Kokkinakis J Pluda AH Friedman I Cokgor MM Haglund DM Ashley J Rich ME Dolan AE Pegg RC Moschel RE McLendon T Kerby JE Herndon DD Bigner SC Schold Jr 1998 Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma J Clin Oncol 16 3570 3575 9817277
86. HS Friedman J Pluda JA Quinn RB Ewesuedo L Long AH Friedman I Cokgor OM Colvin MM Haglund DM Ashley JN Rich J Sampson AE Pegg RC Moschel RE McLendon JM Provenzale ES Stewart S Tourt-Uhlig AM Garcia-Turner JE Herndon 2nd DD Bigner ME Dolan 2000 Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 18 3522 3528 11032594
87. TP Spiro SL Gerson L Liu S Majka J Haaga CL Hoppel ST Ingalls JM Pluda JK Willson 1999 O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair Cancer Res 59 2402 2410 10344750
88. SC Schold Jr DM Kokkinakis SM Chang MS Berger KR Hess D Schiff HI Robins MP Mehta KL Fink RL Davis MD Prados 2004 O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas Neuro Oncol 6 28 32 14769137
89. JA Quinn A Desjardins J Weingart H Brem ME Dolan SM Delaney J Vredenburgh J Rich AH Friedman DA Reardon JH Sampson AE Pegg RC Moschel R Birch RE McLendon JM Provenzale S Gururangan JE Dancey J Maxwell S Tourt-Uhlig JE Herndon 2nd DD Bigner HS Friedman 2005 Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 23 7178 7187 16192602
90. RL Schilsky ME Dolan D Bertucci RB Ewesuedo NJ Vogelzang S Mani LR Wilson MJ Ratain 2000 Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer Clin Cancer Res 6 3025 3031 10955780
91. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon Jr A Walker HS Friedman 2009 Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma Neuro Oncol 11 556 561 19289491
92. J Weingart SA Grossman KA Carson JD Fisher SM Delaney ML Rosenblum A Olivi K Judy SB Tatter ME Dolan 2007 Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial J Clin Oncol 25 399 404 17264335
93. KE Warren AA Aikin M Libucha BC Widemann E Fox RJ Packer FM Balis 2005 Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors J Clin Oncol 23 7646 7653 16234526
94. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh S Gururangan JH Sampson RE McLendon JE Herndon 2nd HS Friedman 2009 Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma Cancer 115 2964 2970 19402172
95. A Broniscer S Gururangan TJ MacDonald S Goldman RJ Packer CF Stewart D Wallace MK Danks HS Friedman TY Poussaint LE Kun JM Boyett A Gajjar 2007 Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report Clin Cancer Res 13 6712 6718 18006772 (Pubitemid 350206808)
96. DM Adams T Zhou SL Berg M Bernstein K Neville SM Blaney 2008 Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study Pediatr Blood Cancer 50 549 553 17941066 (Pubitemid 351155823)
97. JA Quinn SX Jiang J Carter DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon 2nd S Threatt HS Friedman 2009 Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme Clin Cancer Res 15 1064 1068 19188181
98. JA Quinn SX Jiang DA Reardon A Desjardins JJ Vredenburgh JN Rich S Gururangan AH Friedman DD Bigner JH Sampson RE McLendon JE Herndon 2nd A Walker HS Friedman 2009 Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 1262 1267 19204199
99. JA Quinn J Pluda ME Dolan S Delaney R Kaplan JN Rich AH Friedman DA Reardon JH Sampson OM Colvin MM Haglund AE Pegg RC Moschel RE McLendon JM Provenzale S Gururangan S Tourt-Uhlig JE Herndon 2nd DD Bigner HS Friedman 2002 Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma J Clin Oncol 20 2277 2283 11980998
100. ED Batts C Maisel D Kane L Liu P Fu T O'Brien S Remick N Bahlis SL Gerson 2007 O6-benzylguanine and BCNU in multiple myeloma: a phase II trial Cancer Chemother Pharmacol 60 415 421 17354015
101. TF Gajewski J Sosman SL Gerson L Liu E Dolan S Lin EE Vokes 2005 Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma Clin Cancer Res 11 7861 7865 16278409
102. CW Ryan ME Dolan BB Brockstein R McLendon SM Delaney BL Samuels ES Agamah EE Vokes 2006 A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma Cancer Chemother Pharmacol 58 634 639 16520986
103. Sabharwal A, Corrie PG, Midgley RS, Palmer C, Brady J, Mortimer P, Watson AJ, Margison GP, Middleton MR (2009) A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. Cancer Chemother Pharmacol (Epub ahead of print)
104. P Caporaso M Turriziani A Venditti F Marchesi F Buccisano MC Tirindelli E Alvino A Garbin G Tortorelli L Toppo E Bonmassar S D'Atri S Amadori 2007 Novel role of triazenes in haematological malignancies: pilot study of temozolomide, lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia DNA Repair (Amst) 6 1179 1186
105. M Ranson P Hersey D Thompson J Beith GA McArthur A Haydon ID Davis RF Kefford P Mortimer PA Harris S Baka A Seebaran A Sabharwal AJ Watson GP Margison MR Middleton 2007 Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma J Clin Oncol 25 2540 2545 17577032
106. OA Khan M Ranson M Michael I Olver NC Levitt P Mortimer AJ Watson GP Margison R Midgley MR Middleton 2008 A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer Br J Cancer 98 1614 1618 18475294
107. RF Kefford NP Thomas PG Corrie C Palmer E Abdi D Kotasek J Beith M Ranson P Mortimer AJ Watson GP Margison MR Middleton 2009 A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma Br J Cancer 100 1245 1249 19367282
108. AJ Watson MR Middleton G McGown M Thorncroft M Ranson P Hersey G McArthur ID Davis D Thomson J Beith A Haydon R Kefford P Lorigan P Mortimer A Sabharwal O Hayward GP Margison 2009 O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib Br J Cancer 100 1250 1256 19367283
109. AJ Watson A Sabharwal M Thorncroft G McGown R Kerr S Bojanic Z Soonawalla A King A Miller S Waller H Leung GP Margison MR Middleton 2010 Tumor O(6)-methylguanine-DNA methyltransferase inactivation by oral lomeguatrib Clin Cancer Res 16 743 749 20068091
110. D Koch T Hundsberger S Boor B Kaina 2007 Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma J Neurooncol 82 85 89 17031555
111. ME Nelson NA Loktionova AE Pegg RC Moschel 2004 2-amino-O4- benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase J Med Chem 47 3887 3891 15239666
112. S Javanmard NA Loktionova Q Fang GT Pauly AE Pegg RC Moschel 2007 Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2′-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine J Med Chem 50 5193 5201 17880193
113. JM Argiles FJ Lopez-Soriano 1990 Why do cancer cells have such a high glycolytic rate? Med Hypotheses 32 151 155 2142979
114. T Yamamoto Y Seino H Fukumoto G Koh H Yano N Inagaki Y Yamada K Inoue T Manabe H Imura 1990 Over-expression of facilitative glucose transporter genes in human cancer Biochem Biophys Res Commun 170 223 230 2372287
115. J Reinhard U Eichhorn M Wiessler B Kaina 2001 Inactivation of O(6)-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors Int J Cancer 93 373 379 11433402
116. J Reinhard WE Hull CW von der Lieth U Eichhorn HC Kliem B Kaina M Wiessler 2001 Monosaccharide-linked inhibitors of O(6)-methylguanine-DNA methyltransferase (MGMT): synthesis, molecular modeling, and structure-activity relationships J Med Chem 44 4050 4061 11708909
117. RB Roth LD Samson 2000 Gene transfer to suppress bone marrow alkylation sensitivity Mutat Res 462 107 120 10767622
118. H Geiger D Schleimer KJ Nattamai SR Dannenmann SM Davies BD Weiss 2006 Mutagenic potential of temozolomide in bone marrow cells in vivo Blood 107 3010 3011 16554488
119. BH Kushner MP Laquaglia K Kramer S Modak NK Cheung 2008 Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide Pediatr Blood Cancer 51 552 554 18570300
120. S De Vita S De Matteis L Laurenti P Chiusolo G Reddiconto A Fiorini G Leone S Sica 2005 Secondary Ph + acute lymphoblastic leukemia after temozolomide Ann Hematol 84 760 762 16044311
121. YW Su MC Chang MF Chiang RK Hsieh 2005 Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma J Neurooncol 71 315 318 15735923
122. JA Allay LL Dumenco ON Koc L Liu SL Gerson 1995 Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells Blood 85 3342 3351 7756667
123. T Moritz W Mackay BJ Glassner DA Williams L Samson 1995 Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo Cancer Res 55 2608 2614 7780976
124. J Jelinek LJ Fairbairn TM Dexter JA Rafferty C Stocking W Ostertag GP Margison 1996 Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase Blood 87 1957 1961 8634444
125. R Maze JP Carney MR Kelley BJ Glassner DA Williams L Samson 1996 Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1- nitrosourea, a chemotherapeutic alkylating agent Proc Natl Acad Sci U S A 93 206 210 8552605
126. JA Allay BM Davis SL Gerson 1997 Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice Exp Hematol 25 1069 1076 9293904
127. ME Dolan AE Pegg LL Dumenco RC Moschel SL Gerson 1991 Comparison of the inactivation of mammalian and bacterial O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine and O6-methylguanine Carcinogenesis 12 2305 2309 1747932
128. NA Loktionova AE Pegg 1996 Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N′-bis (2-chloroethyl)-N-nitrosourea Cancer Res 56 1578 1583 8603405
129. TM Crone K Goodtzova S Edara AE Pegg 1994 Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine Cancer Res 54 6221 6227 7954470
130. M Xu-Welliver S Kanugula AE Pegg 1998 Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine Cancer Res 58 1936 1945 9581836
131. LB Woolford TD Southgate GP Margison MD Milsom LJ Fairbairn 2006 The P140K mutant of human O(6)-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine J Gene Med 8 29 34 16075413
132. BM Davis JC Roth L Liu M Xu-Welliver AE Pegg SL Gerson 1999 Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy Hum Gene Ther 10 2769 2778 10584923
133. BM Davis JS Reese ON Koc K Lee JE Schupp SL Gerson 1997 Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea Cancer Res 57 5093 5099 9371508
134. ON Koc JS Reese BM Davis L Liu KJ Majczenko SL Gerson 1999 DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts Hum Gene Ther 10 1021 1030 10223735
135. EL Kreklau KE Pollok BJ Bailey N Liu JR Hartwell DA Williams LC Erickson 2003 Hematopoietic expression of O(6)-methylguanine DNA methyltransferase-P140K allows intensive treatment of human glioma xenografts with combination O(6)-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea Mol Cancer Ther 2 1321 1329 14707273
136. JS Reese BM Davis L Liu SL Gerson 1999 Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide Clin Cancer Res 5 163 169 9918215
137. N Sawai S Zhou EF Vanin P Houghton TP Brent BP Sorrentino 2001 Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector Mol Ther 3 78 87 11162314
138. M Jansen UR Sorg S Ragg M Flasshove S Seeber DA Williams T Moritz 2002 Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells Cancer Gene Ther 9 737 746 12189523
139. S Cai A Ernstberger H Wang BJ Bailey JR Hartwell AL Sinn O Eckermann Y Linka WS Goebel H Hanenberg KE Pollok 2008 In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector Exp Hematol 36 283 292 18279716
140. SP Zielske SL Gerson 2002 Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to -BG/BCNU and allows selection in vitro Mol Ther 5 381 387 11945064
141. P Maier I Spier S Laufs MR Veldwijk S Fruehauf F Wenz WJ Zeller 2010 Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K) Gene Ther 17 389 399 19865182
142. M Christmann MT Tomicic WP Roos B Kaina 2003 Mechanisms of human DNA repair: an update Toxicology 193 3 34 14599765
143. B Kaina M Christmann 2002 DNA repair in resistance to alkylating anticancer drugs Int J Clin Pharmacol Ther 40 354 367 12467304
144. J Lips B Kaina 2001 DNA double-strand breaks trigger apoptosis in p53-deficient fibroblasts Carcinogenesis 22 579 585 11285192
145. LF Batista WP Roos M Christmann CF Menck B Kaina 2007 Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks Cancer Res 67 11886 11895 18089819